Akoya Biosciences, Inc. (AKYA)
NASDAQ: AKYA · Real-Time Price · USD
1.260
-0.060 (-4.55%)
Jun 12, 2025, 4:00 PM - Market closed
Akoya Biosciences Employees
Akoya Biosciences had 205 employees as of December 31, 2024. The number of employees decreased by 125 or -37.88% compared to the previous year.
Employees
205
Change (1Y)
-125
Growth (1Y)
-37.88%
Revenue / Employee
$390,054
Profits / Employee
-$231,868
Market Cap
62.84M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 205 | -125 | -37.88% |
| Dec 31, 2023 | 330 | -39 | -10.57% |
| Dec 31, 2022 | 369 | 50 | 15.67% |
| Dec 31, 2021 | 319 | 150 | 88.76% |
| Dec 31, 2020 | 169 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
AKYA News
- 20 days ago - Kent Lake Responds to Quanterix's Post-Effective Amendment and Akoya's Superior $1.40-per-Share Alternative Proposal - PRNewsWire
- 4 weeks ago - Akoya Biosciences Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 5 weeks ago - AKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYA - Business Wire
- 6 weeks ago - Kent Lake Issues Statement on Quanterix's Blatant Disregard for Will of Shareholders - Business Wire
- 6 weeks ago - Quanterix and Akoya Biosciences Announce Amended Merger Agreement - Business Wire
- 7 weeks ago - Akoya Biosciences and Enable Medicine Launch the Largest Commercially Available Single-Cell Spatial Proteomics Atlas - GlobeNewsWire
- 7 weeks ago - Akoya Biosciences Expands Biopharma Service Portfolio with New ADC Breast Cancer Assay and Real-world IO60 Insights at AACR 2025 - GlobeNewsWire
- 7 weeks ago - Akoya Biosciences and Singapore Translational Cancer Consortium (STCC) Partner on SUPER Study Designed to Advance Cancer Immunophenotyping for Patients in Singapore - GlobeNewsWire